PREVENT partners
Funding partners | R & D partners
VIDO/InterVac | The Canadian Center of Vaccinology | The BC Centre for Disease Control
Research | Facilities
The Canadian Center for Vaccinology
Facilities
The Canadian Center for Vaccinology is a 30,000 square foot vaccine research centre for basic translational science, epidemiology and clinical trials (Phases I-III), and implementation and evaluative policy research.
The Center's facilities include laboratories for microbiological and molecular research, ambulatory clinical trial facilities, and data analysis, training, and videoconferencing / telemedicine capabilities and a Containment Level 3 laboratory and a human vaccine challenge unit.
The "sanofi pasteur human vaccine challenge unit," a 5,400 sq. ft., ten-bed inpatient unit with isolation rooms, will be the first of its kind in Canada and, with less than a dozen such facilities worldwide, at the cutting edge of global vaccine research.
The Canadian Center for Vaccinology serves as an "academic pipeline" for Canadian vaccine priorities identified through the National Immunization Strategy. It facilitates public health policy development by enabling policy makers and planners to obtain scientific data upon which to base their decisions and evaluate the outcomes of implemented policies. As one of the three partner institutions in the recently formed Pan-Provincial Vaccine Enterprise (PREVENT), the CCfV will play an integral role in accelerating promising Canadian vaccine discoveries through preclinical and early clinical evaluation and catalyzing the commercialization of viable products that meet Canada's public health priorities.
The CCfV in Halifax, together with other vaccine centres elsewhere in Canada such as in British Columbia (Vaccine Evaluation Center and the BC Centre for Disease Control, Vancouver), Saskatchewan (Vaccine and Infectious Disease Organization, Saskatoon), and Quebec (McGill University, Montreal, and Institut national de santé publique du Québec, Quebec City), form a nationwide network for collaborative and complementary vaccine research.
